Semaglutide, the first weight loss drug approved by the U.S. Food and Drug Administration to reduce the risk of major adverse cardiovascular events, improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men according to a new study from Dr. Mikhail Kosiborod, Vice President of Research at Saint Luke's Health System. Dr. Kosiborod recently presented the new research at the American Diabetes Association’s 2024 Scientific Sessions. Read more: https://bit.ly/3RHPXQU
Saint Luke's Health System’s Post
More Relevant Posts
-
Professor Rameen Shakur MPhil M.D. Ph.D(Cantab)FRSA FIBMS FRSB MIoD FRSPH
Professor Rameen Shakur MPhil M.D. Ph.D(Cantab)FRSA FIBMS FRSB MIoD FRSPH is an Influencer Director Centre Precision Health and Translational Medicine. Professor of Genomics & Precision Cardiovascular Medicine ,CEO, Group leader. Ai & medtech company founder.Author.Founder Cambridge Heartwear.My own views.
It was nice to give some perspective on BBC News and DailyMail.com on the recent data from the SELECT trial and how the new data on CArdiovascular risk reduction mortality of up to 20 percent with semeglutide in diabetic, obese patients with prior cardiovascular risk . It’s important to acknowledge no doubt this is a big addition to our armoury against obesity , diabetes and chronic disease management , but it is not the be all and end all, we must look at the patient holistically and use these new therapies in a stratified manner. The population health economics has not been modelled fully yet, and this is something we certainly need more understanding on the mechanism of action of the GLP-1 agonists and how cardiac protection is conferred directly so to be better guided on how the biology is really being impacted. #obesity #SELECTtrial #semaglutide #cardiovascularrisk #cardiology #CV #populationhealth #GLP1 #diabetes #precisionhealth #ozempic #wegovy https://lnkd.in/e3qrgDUx
Weight loss jab could reduce heart attack risk, study finds
bbc.co.uk
To view or add a comment, sign in
-
Executive Board Advisor & Consultant. International scaleup. Go-to-market options. Optimising international scaleup through distributors. Improving business development success in complex sales for B2B service providers.
Is this a good story or marketing hype and froth on the cappuccino? Without the details of the study, it is very difficult to say. Why? Because the key determinant that is not mentioned is not absolute risk reduction, but relative additional risk reduction over a statin. In other words, statins have proven risk reductions for heart attack and stroke. They are now generic, which means they are cheap. So what we need to ask is: "If these obese patients with cardiovascular risks greater than 20% are put on a statin (NICE guidelines), then what extra reduction is achieved by adding in semaglutide (expensive), and is that additional risk reduction cost-effective?" This question is not answered. If I were NICE assessors, I'd guess the additional risk reduction over a statin is very small and unlikely to be cost-effective. I've been around too long in this "game" to know that the easy comparator is placebo. The real comparator is the current standard of care in cardiovascular risk reduction (statin and ACE inhibitor or ARB for hypertension). Were patients excluded in this SELECT trial if they were hypertensive and/or taking a statin? Without such forensic examination, it may be just marketing hype because it may not represent clinical management of risks. As always, the devil is in the detail. Don't get too excited just yet. I'll stick to my cocktail of 20mg atorvastatin and an ACE inhibitor, thank you - shaken, not stirred. #obesity #cardiovascularrisk #semaglutide
Weight loss jab could reduce heart attack risk, study finds
bbc.co.uk
To view or add a comment, sign in
-
Can a popular anti-obesity medication lower your chances of a heart attack, stroke, or cardiovascular death? In March, the Food and Drug Administration (FDA) approved semaglutide (brand name: Wegovy®) for just that purpose after a study published last November showed that the drug lowers certain people’s risk for those events by as much as 20%. Here, Harlan Krumholz, MD, SM, Yale Medicine cardiologist, answers four questions about semaglutide and cardiac risk: https://brnw.ch/21wHPTr #semaglutide #wegovy #SELECT #heartattack #stroke #obesity
Why Your Cardiologist May Prescribe Semaglutide (Wegovy)
yalemedicine.org
To view or add a comment, sign in
-
A recent study by Aleksi V, Elise K, and Koskela TH, published in *BMC Research Notes*, highlights a concerning trend of excessive thyroid hormone use among fibromyalgia patients, particularly involving triiodothyronine (T3). T3 is believed to help alleviate fibromyalgia symptoms such as fatigue and pain due to its role in regulating metabolism and energy levels. However, this practice poses significant cardiovascular risks, including increased heart rate, arrhythmias, and a higher incidence of cardiovascular disease. The cross-sectional analysis conducted in primary healthcare settings found a notable prevalence of overprescription. Healthcare providers are urged to monitor thyroid levels closely, avoid unnecessary T3 supplementation, and conduct regular cardiovascular assessments to mitigate these risks. This study underscores the need for careful management of thyroid hormone therapy in fibromyalgia to balance symptom relief with cardiovascular health.
To view or add a comment, sign in
-
-
Employer-Sponsored Benefits | Human Capital Management | Data-Driven Decision Making | Process Excellence | MBA
Interesting data released from a new GLP-1 study: 1. Initial clinical findings of 15% weight loss were driven, in part, by lifestyle interventions. The new study still showed an average of 10% sustained weight loss over 208 weeks without these interventions. 2. The study looked at patients who had been using the drug for over 4 years and found no adverse health impacts. 3. Potentially the most interesting finding is that the cardiovascular benefits are not driven by weight loss alone, with the predominant theory being that GLP-1s reduce inflammation in the body driving improved cardiovascular health. #GLP1 #semaglutide #wegovy #weightloss #cardiovascularhealth https://lnkd.in/eBF968Sf
What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
msn.com
To view or add a comment, sign in
-
Past President Argentine Lipid Society. Internal Medicine physician and Lipidologist. Pharmacology Professor at FASTA University, School of Medicine.
👉Modification of lipoprotein metabolism and function driving atherogenesis in diabetes ☝️ Inference of clinical intervention studies identify the number of ApoB-containing lipoproteins as a stronger driver of the pathological processes resulting in clinical outcomes than their composition in triglycerides and cholesterol. This emphasizes the need to evaluate levels of circulating ApoB, in association to LDL-C and non-HDL-C, as marker of cardiovascular risk in diabetic patients not only in tertiary care settings 🔓Open access https://lnkd.in/ddytwvnV European Atherosclerosis Society
To view or add a comment, sign in
-
-
Great to be back after the festive season and the indulgence. Some may have missed important messages from the SURMOUNT-4 trial. Participants who switched from Tirzapetide to placebo at 36 weeks experienced 14% weight gain after a year, while those who continued on tirzapetide had a further 5.5% weight loss. Participants who switched to placebo maintained some weight loss (9.9% from study baseline) but reversed all cardiometabolic factors as waist circumference, hemoglobin A1c, fasting glucose, insulin, lipid levels, and systolic and diastolic blood pressure. This supports every reason to continue tirzapetide and similar medications. #cardiometabolic #tirzepatide
Effect of Tirzepatide on Maintenance of Weight Reduction
jamanetwork.com
To view or add a comment, sign in
-
"#Hypertension (high blood pressure) affects approximately one-third of adults and is a major risk factor for cardiovascular diseases, renal diseases and dementia, creating enormous health and economic burdens globally. The #Kidney controls blood pressure by regulating fluid and electrolyte homeostasis. Integral to this process is the NCC, a sodium–chloride cotransporter, which has a major role in fine-tuning urinary Na+ and Cl− excretion, regulating ion and acid–base balance, and controlling #BloodPressure! Decreased activity of the NCC underlies #GitelmanSyndrome, while increased activity of the NCC underlies #PseudoHypoAldosteronism Type II. Thus, the NCC is a prime #DrugTarget of pharmacological therapies for #Renal and #Cardiovascular disorders, including thiazide #Diuretics! Thiazide diuretics were the first oral antihypertensive #Drugs with decent #Efficacy and safety and remain the preferred first-line antihypertensive drugs. Despite being among the most widely prescribed drugs, the #MechanismOfAction (MoA) of thiazide diuretics selectively inhibition of and electroneutral transport of Na+ and Cl− via NCC remains elusive!" Do not miss this amazing article published in the Nature Magazine in which Liang Feng and colleagues from Stanford University School of Medicine determined the #CryoEM structures of human NCC alone and in complex with a commonly used thiazide diuretic: https://lnkd.in/eBigan2i These structures, together with functional studies, reveal major conformational states of the NCC and an intriguing regulatory MoA. They also illuminate how thiazide diuretics specifically interact with the NCC and inhibit its #Transport function! Overall, these results provide critical insights for understanding the Na–Cl cotransport mechanism of the NCC, and they establish a framework for future #DrugDesign and #DrugDevelopment as well as for interpreting disease-related mutations! If you are interested in how Cryo-EM is revolutionizing #DrugDiscovery, please follow this weblink to gain some deeper insights from there: https://lnkd.in/eXW7K_U6
To view or add a comment, sign in
-
-
GLP-1s for Obesity: Your Questions Answered: Should patients combine intermittent fasting with GLP-1 agents? Are the drugs safe in kidney patients? Experts from the recent Medscape Masters event on obesity answer your questions. Medscape Medical News
GLP-1s for Obesity: Your Questions Answered
medscape.com
To view or add a comment, sign in
-
Exciting News in Obesity Treatment! Prof Jerry Greenfield of St Vincent’s Clinic and the Garvan Institute of Medical Research discusses new medications targeting GLP-1 and GIP receptors which offer hope for effective obesity management. They reduce appetite, help with weight loss, and assist insulin release for type 2 diabetes patients. Some side effects, like nausea, are manageable. However, a shortage of semaglutide (Ozempic) is expected in 2023-2024, highlighting growing demand. The newly approved tirzepatide (Mounjaro) can help shed 15-20 kilograms. While these treatments show promise, caution is needed for individuals with specific medical histories and potential stomach issues before certain procedures. Excitingly, the future holds the potential for "Triple G" receptor agonists, offering even more effective weight loss solutions. Read more: https://lnkd.in/gZDe7ZAS St Vincent's Clinic Research Foundation. #ObesityTreatment #HealthcareInnovation #StVincentsClinic #Endocrinology #DiabetesManagement
To view or add a comment, sign in
-